Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro

British Journal of Cancer

Volumn 73, Issue 8, 1996, Pages 952-960

  Siim, B G ^a   Van Zijl, P L ^a   Brown, J M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioreductive drug; DNA damage; Hypoxia; Metabolism; Tirapazamine

Indexed keywords

3 AMINO 1,2,4 BENZOTRIAZINE 1 OXIDE; TIRAPAZAMINE;

ANIMAL CELL; ARTICLE; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIC CELL; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0030009223     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.187     Document Type: Article

References (52)

1. BARHAM HM, PATTERSON A, CHINJE EC, HARRIS AL AND STRATFORD IJ. (1995). Sensitivity to tirapazamine (SR 4233) is determined by P450 reductase activity in human breast but not lung cancer cell lines. Br. J. Cancer, 71 (Supp. XXIV), 20.
2. BIEDERMANN KA, WANG J, GRAHAM RP AND BROWN JM. (1991). SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br. J. Cancer, 63, 358-362.
3. BROWN JM. (1993). SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer, 67, 1163-1170.
4. BROWN JM AND GIACCIA AJ. (1994). Tumour hypoxia: the picture has changed in the 1990s. Int. J. Radiat. Biol., 65, 95-102.
5. BROWN JM AND KOONG A. (1991). Therapeutic advantage of hypoxic cells in tumors: A theoretical study. J. Natl Cancer Inst., 83, 178-185.
6. BROWN JM AND LEMMON MJ. (1990). Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res., 50, 7745-7749.
7. BROWN JM AND LEMMON MJ. (1991). Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int. J. Radiat. Oncol. Biol. Phys., 20, 457-461.
8. BUSH RS, JENKIN RDT, ALLT WEC, BEALE FA, BEAN H, DENBO AJ AND PRINGLE JF. (1978). Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer, 37 (Suppl. III), 302-306.
9. COLE S, STRATFORD IJ, FIELDEN EM, ADAMS GE, LEOPOLD W, ELLIOTT W, SUTO M AND SEBOLT-LEOPOLD J. (1992). Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908). Int. J. Radiat. Oncol. Biol. Phys., 22, 545-548.
10. DENNY WA AND WILSON WR. (1993). Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev., 12, 135-151.
11. DOHERTY N, HANCOCK SL, KAYE S, COLEMAN CN, SHULMAN L, MARQUEZ C, MARISCAL C, RAMPLING R, SENAN S AND ROEMELING RV. (1994). Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int. J. Radiat. Oncol. Biol. Phys., 29, 379-382.
12. DORIE MJ AND BROWN JM. (1993). Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res., 53, 4633-4636.
13. DURAND RE. (1994). The influence of microenvironmental factors during cancer therapy. In vivo, 8, 691-702.
14. GATENBY RA, KESSLER HB, ROSENBLUM JS, COIA LR, MOLDOFSKY PJ, HARTZ WH AND BRODLER GJ. (1988). Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 14, 831-838.
15. HIRST DG, BROWN JM AND HAZLEHURST JL. (1983). Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res., 43, 1961-1965.
16. 2 tension measurements. Cancer Res., 51, 6098-6102.
17. 2 predicts survival in advanced cancer of the uterine cervix. Radtother. Oncol., 26, 45-50.
18. HUGHES CS, SHEN JW AND SUBJECK JR. (1989). Resistance to etoposide induced by three glucose-regulated stresses in Chinese hamster ovary cells. Cancer Res., 49, 4452-4454.
19. KIM IH AND BROWN JM. (1994). Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int. J. Radiat. Oncol. Biol. Phys., 29, 493-497.
20. KOCH CJ. (1993). Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res., 53, 3992-3997.
21. MARSHALL RS AND RAUTH AM. (1986). Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant. Cancer Res., 46, 2709-2713.
22. MARSHALL RS AND RAUTH AM. (1988). Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells. Cancer Res., 48, 5655-5659.
23. MOSELEN JW, HAY MP, DENNY WA AND WILSON WR. (1995). N-[2-(2-methyl-5-nitroimidazolyl) ethyl]-4-(2-nitroimidazolyl) butanamide (NNB, NSC 639862), a bis-nitroimidazole with enhanced selectivity as a bioreductive drug. Cancer Res., 55, 574-580.
24. MUELLER-KLEISER W, SCHLENGER KH, WALENTA S, GROSS M, KARBACH U, HOECKEL M AND VAUPEL P. (1991). Pathophysiological approaches to identifying tumor hypoxia in patients. Radiother. Oncol., 1, 21-28.
25. OLIVE PL. (1995a). Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine. Br. J. Cancer, 71, 529-536.
26. OLIVE PL. (1995b). Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. II. RSU 1069. Br. J. Cancer, 71, 537-542.
27. OLIVE PL AND DURAND RE. (1992). Detection of hypoxic cells in a murine tumor with the use of the Comet Assay. J. Natl Cancer Inst., 84, 707-711.
28. OLIVE PL, BANATH JP AND DURAND RE. (1990). Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the 'comet' assay. Radiat. Res., 122, 86-94.
29. OLIVE PL, WLODEK D AND BÁNATH JP. (1991). DNA double-strand breaks measured in individual cells subjected to gel electrophoresis. Cancer Res., 51, 4671-4676.
30. OLIVE PL, WLODEK D, DURAND RE AND BÁNATH JP. (1992). Factors influencing DNA migration from individual cells subjected to gel electrophoresis. Exp. Cell Res., 198, 259-267.
31. OLIVE PL, DURAND RE, LE RICHE J, OLIVOTTO IA AND JACKSON SM. (1993a). Gel electrophoresis of individual cells to quantify hypoxic fraction in human breast cancers. Cancer Res., 53, 733-736.
32. OLIVE PL, FRAZER G AND BANÁTH JP. (1993b). Radiation-induced apoptosis measured in TK6 human B lymphoblast cells using the comet assay. Radiat Res., 136, 130-136.
33. ÖSTLING O AND JOHANSON KJ. (1984). Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem. Biophys. Res. Commun., 123, 291-298.
34. PATTERSON AV, BARHAM HM, CHINJE EC, ADAMS GE, HARRIS AL AND STRATFORD IJ. Importance of P450 reductase activity in determining sensitivity of breast tumor cells to the bioreductive drug tirapazamine (SR 4233). Br. J. Cancer, 72, 1144-1150.
35. PLUMB JA, GERRITSEN M AND WORKMAN P. (1994). DT-diaphorase protects cells from the hypoxic cytotoxicity of the indoloquinone EO9. Br. J. Cancer, 70, 1136-1143.
36. ROBERTSON N, HAIGH A, ADAMS GE AND STRATFORD IJ. (1994). Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur. J. Cancer, 30A, 1013-1019.
37. ROCKWELL SC, KALLMAN RF AND FAJARDO LF. (1972). Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J. Natl Cancer Inst., 49, 735-749.
38. SEBOLT-LEOPOLD JS, ELLIOT WL, SHOWALTER HD AND LEOPOLD WR. (1993). Rationale for selection of PD 144872, the R isomer of RB 6145, for clinical development as a radiosensitizer. Proc. Am. Assoc. Cancer Res., 34, 362.
39. SIIM BG, ATWELL GJ AND WILSON WR. (1994). Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. Br. J. Cancer, 70, 596-603.
40. SILVA JM AND O'BRIEN PJ. (1993). Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions. Br. J. Cancer, 68, 484-491.
41. STRATFORD IJ AND STEPHENS MA. (1989). The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int. J. Radiat. Oncol. Biol. Phys., 16, 973-976.
42. STRATFORD IJ, O'NEILL P, SHELDON PW, SILVER ARJ AND WALLING JM. (1986). RSU 1069, a nitroimidazole compound containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem. Pharmacol., 35, 105-109.
43. TANNOCK IF. (1978). Cell kinetics and chemotherapy: A critical review. Cancer Treat. Rep., 62, 1117-1133.
44. TWENTYMAN PR, BROWN JM, GRAY JW, FRANKO AJ, SCOLES MA AND KALLMAN RF. (1980). A new mouse tumor model system (RIF-1) for comparison of end-point studies. J. Natl Cancer Inst., 64, 595-604.
45. 2 tension measurements. Cancer Res., 51, 3316-3322.
46. WANG J, BIEDERMANN KA AND BROWN JM. (1992). Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res., 52, 4473-4477.
47. WILSON WR AND DENNY WA. (1992). DNA-binding nitroheterocycles as hypoxia-selective cytotoxins. In Radiation Research: A Twentieth-Century Perspective, Dewey WC, Edington M, Fry RJM, Hall EJ and Whitmore GF (eds) pp. 796-801. Academic Press: New York.
48. WORKMAN P AND STRATFORD IJ. (1993). The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev., 12, 73-82.
49. ZEMAN EM AND BROWN JM. (1989). Pre- and post-irradiation radiosensitization by SR 4233. Int. J. Radiat. Oncol. Biol. Phys., 16, 967-971.
50. ZEMAN EM, BROWN JM, LEMMON MJ, HIRST VK AND LEE WW. (1986). SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 12, 1239-1242.
51. ZEMAN EM, HIRST VK, LEMMON MJ AND BROWN JM. (1988). Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother. Oncol., 12, 209-218.
52. ZHANG H, KOCH CJ, WALLEN CA AND WHEELER KT. (1995). Radiation-induced DNA damage in tumors and normal tissues. III. Oxygen dependence of the formation of strand breaks and DNA-protein crosslinks. Radiat. Res., 142, 163-168.